CD&R, Merck GHI, and McKesson Ventures Invest in Innovative Oncology Data and Informatics Company M2GEN Investment to Accelerate Development of Next Gen Cancer Therapies with the Mission to Transform Patient Care News provided by Share this article Share this article TAMPA, Fla. and NEW YORK, March 17, 2021 /PRNewswire/ -- M2GEN today announced a significant new investment by Clayton, Dubilier & Rice ("CD&R") funds, the Merck Global Health Innovation Fund ("Merck GHI"), and McKesson Ventures to recapitalize M2GEN, a leading oncology data and informatics platform focused on transforming cancer care, in partnership with its existing shareholders. The financial terms of the transaction, which closed today, were not disclosed.